India recorded 2,86,384 fresh Covid-19 cases in the last 24 hours, marginally higher than the previous day figure. 3,06,357 patients recovered during the last 24 hours.
The recovery rate reaches at 93.33%. The daily positivity rate reaches at 19.59%.
India’s active caseload currently stands 22,02,472, active cases stand at 5.46%
Relatively, four states namely Delhi, Madhya Pradesh, Uttar Pradesh and Gujarat reported maximum Covid-19 fresh cases in the last 24 hours, with all four of them recording 7,498, 9,966, 10,937 and 14,781 cases respectively.
Three states that recorded more than 35,000 fresh Covid-19 cases in the last 24 hours are- Maharashtra, Kerala and Karnataka
Maharashtra reported 35,756 new cases in the last 24 hours. Kerala reported 49,771 fresh Covid-19 cases, 34,439 recoveries, and 63 deaths in the last 24 hours. Karnataka logged 48,905 new cases and 39 deaths yesterday.
In a bid to ramp up the vaccination process, the country has administered the cumulative figure of 163.84 crore vaccine doses so far. The price of Covishield and Covaxin, the Covid vaccines which are expected to soon get regular market approval from India’s drug regulator, is likely to be capped at Rs 275 per dose with an additional service charge of Rs 150. As of now, Covaxin is priced at Rs 1,200 per dose while Covishield costs Rs 780 in private facilities.
An ICMR study has found that individuals infected with the Omicron variant have significant immune response that could neutralise not only this strain but others like the prevalant Delta variant. The study analysed the IgG and neutralising antibodies (NAbs) against B.1, Alpha, Beta, Delta, and Omicron variants with the sera of individuals infected with the Omicron variant. It suggests that the immune response induced by the Omicron could effectively neutralise the Delta variant, making re-infection with the Delta variant less likely and displacing this variant as the dominant strain.
US biotech company Moderna announced on Wednesday that it has begun clinical trials of a booster dose of vaccine designed specifically to combat the Omicron variant. The trials will involve a total of 600 adults half of whom have already received two doses of Moderna’s Covid-19 vaccine at least six months ago and half of whom have received two doses plus the previously authorized booster dose.